Edwards Lifesciences, a provider of products to treat cardiovascular disease, has reported net income for the third quarter ending Sept. 30, of $29.1 million compared to net income of $27.8 million for the same period in 2006.

Sales increased 5.7 percent to $261.4 million from $247.4 million a year ago because growth in heart valve therapy, critical care and vascular franchises offset a decline in cardiac surgery systems sales, according to the Irvine, Calif.-based Edwards
For the third quarter, Edwards’ gross profit margin was 65.3 percent compared to 64.7 percent in the same period last year.